31 Mar 2026 | 3 Mins Read
Biocon reduces workforce ahead of Biologics merger completion
Flipitmoney
Biocon is undertaking organisational rationalisation as it completes its $5.5 billion integration of biologics and generics businesses. Around 200–300 employees across functions are impacted, with exiting staff receiving three months’ salary and variable pay, with the move stated as mutual and not performance-related.